Skip to main
  1. Stocks
  2. Pacira Pharmaceuticals
  3. Forecast
PCRX

Pacira Pharmaceuticals (PCRX) Stock Forecast & Price Target

Pacira Pharmaceuticals (PCRX) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 11%
Hold 78%
Sell 0%
Strong Sell 0%

Bulls say

Pacira BioSciences is viewed positively because Viatris’s $36.50-per-share all-cash offer validates the company’s underappreciated commercial franchise and platform optionality while delivering a ~45% premium and ~$1.65B equity value. The deal price is supported by more than $50M of annual run-rate cost synergies, which, when capitalized, largely explains the gap above the prior standalone DCF value of about $25/sh and implies Pacira’s assets are being monetized at roughly 9.3x LTM adjusted EBITDA. Strategically, Pacira adds EXPAREL ($587M LTM revenue), ZILRETTA ($121M), a ~340-person specialty sales force, international expansion rights, and PCRX-201 gene-therapy upside, all of which strengthen the bull case despite litigation and execution risks.

Bears say

Pacira BioSciences is viewed negatively because a failed or terminated transaction could send shares back below pre-announcement levels, with the market likely penalizing the company for the negative signaling effect of a broken deal. The downside case hinges on execution and regulatory uncertainty, including failure to meet the >50% minimum tender condition, a material adverse change, or FTC/antitrust intervention, while also exposing investors to deal-mechanics risk, concentration risk, and liquidity risk. Beyond the transaction, the business still faces commercial and supply chain risk, clinical and regulatory risk, competitive pressure, partnership risk, and intellectual property and legal challenges across EXPAREL, ZILRETTA, iovera, and PCRX-201.

Pacira Pharmaceuticals (PCRX) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 11% recommend Buy, 78% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pacira Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Pacira Pharmaceuticals (PCRX) Analyst Forecast & Price Prediction

Get the latest Pacira Pharmaceuticals (PCRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Pacira Pharmaceuticals (PCRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pacira Pharmaceuticals (PCRX) Forecast

Analysts have given Pacira Pharmaceuticals (PCRX) a Hold based on their latest research and market trends.

According to 9 analysts, Pacira Pharmaceuticals (PCRX) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pacira Pharmaceuticals (PCRX)


Pacira Pharmaceuticals (PCRX) Analyst Forecast & Price Prediction

Get the latest Pacira Pharmaceuticals (PCRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Pacira Pharmaceuticals (PCRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PCRX stock data and trends